|
 |
||
      |
|
|
» Apply for a Grant
- FAQs - Young Investigator - Independent Investigator - Distinguished Investigator - Staglin Award » Grantee List - Young Investigators - Independent Investigators - Distinguished Investigators - Staglin Awards
» Prizes
- Lieber Prize - Falcone Prize - Ruane Prize - Goldman-Rakic Prize - Freedman Award - Klerman Award » For Grantees - Young Investigator Fact Sheet - Independent Investigator Fact Sheet - Distinguished Investigator Fact Sheet - Staglin Award Fact Sheet 
|
 Project Summary  Kent Jardemark, Ph.D. (Young Investigator 2000) of State University of New York, Stony Brook, will compare the similarities and differences in the ability of atypical and typical antipsychotic medications to reduce or prevent effects of repeated treatment with the drug PCP (angel dust). Previous results show that clozapine but not haloperidol prevents NMDA receptors from being oversensitized following administration of PCB in the prefrontal cortex. The results from this study should improve our understanding of the ability of atypical antipsychotic medications to alleviate negative symptoms and improve cognitive and executive skills in patients with schizophrenia. Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia |
Announcements
NARSAD Award Winners
 Colleen Ann McClung, Ph.D., UT Southwestern Medical Center at Dallas, 2005 & 2007 Young Investigator Latest News from NARSAD
|
